NCT00430144View on ClinicalTrials.gov

Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

October 31, 2010

Conditions
Cervical Cancer
Interventions
DRUG

Belotecan(CKD-602)

Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle

Trial Locations (1)

Unknown

National cancer center, Seoul

All Listed Sponsors
lead

Sokbom Kang

OTHER_GOV

NCT00430144 - Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix | Biotech Hunter | Biotech Hunter